Slide 1: Interim report January – September 2021
VITROLIFE AB (PUBL) Interim report January – September 2021 2021-10-29 Thomas Axelsson, CEO Mikael Engblom, CFO 1
Slide 2: Profitable growth and Igenomix acquisition
PROFITABLE GROWTH AND IGENOMIX ACQUISITION Q3: § Sales of 406 MSEK (320) equals +27% in SEK. § Sales increased by 30% in local currency. § EBITDA of 162 MSEK (134) corresponding to a margin of 40%. § Agreement to acquire 100% of Igenomix Jan-Sep: § Sales of 1,167 MSEK (863) equals +35% in SEK. § Sal
Slide 3: Sales and growth per market region
SALES AND GROWTH PER MARKET REGION SHARE OF VITROLIFE’S SALES ROLLING 12-MONTHS 18% 44% 22% 16% Q3 GROWTH RATE COMPARED TO LAST YEAR IN LOCAL CURRENCIES +26% +17% +33% +35% Total +30%* 3 * Whereof organic growth +30 percent
Slide 4: Sales and growth per division
SALES AND GROWTH PER DIVISION SEK millions, rolling 12m 1600 1400 125 136 142 GENOMICS +43% 129 91 116 102 1200 109 107 488 442 488 506 438 TECHNOLOGY +81% 1000 446 397 391 363 800 600 871 893 400 834 842 835 746 750 752 768 CONSUMABLES +12% 200 0 Quarterly growth, Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 local c
Slide 5: Creates a global leader in reproductive health
CREATES A GLOBAL LEADER IN REPRODUCTIVE HEALTH Joins two of the strongest names within reproductive health into one integrated platform Creates a global leader in reproductive health technology with sales in excess of SEK 2 billion Enables Vitrolife to better serve clinics, professionals and patient
Slide 6: Innovative embryo evaluation and leading diagnostic tool to find window of implantation
INNOVATIVE EMBRYO EVALUATION AND LEADING DIAGNOSTIC TOOL TO FIND WINDOW OF IMPLANTATION Two of the strongest names within reproductive health into one platform to achieve successful treatment outcomes Two methods for embryo evaluation Combination improves successful treatment outcomes Best-in-class
Slide 7: Structure, terms, time plan and financial impact
STRUCTURE, TERMS, TIME PLAN AND FINANCIAL IMPACT § Acquisition of 100% of the share capital in Igenomix for a total consideration of EUR 1,250 million (SEK 12.7 billion1) on a cash and debt free basis, from EQT and other shareholders. § Financed through a mix of a share issue in kind directed to the
Slide 8: Key financials Group Q3
KEY FINANCIALS GROUP Q3 • Fluctuations in exchange rates positively impacted EBITDA by SEK 1 million. • EBITDA included acquisition-related one-time costs of SEK 8 million. Adjusted EBITDA amounted to SEK 170 million, corresponding to a margin of 42 percent. 2021 2020 2021 2020 2020 Q3 Q3 Q1-Q3 Q1-Q
Slide 9: Long-term outlook
LONG-TERM OUTLOOK § Long-term market growth 5-10% in monetary terms § Expansion of sales § Broadening the product offering 9
Slide 10: Contact
Contact: Thomas Axelsson, CEO, taxelsson@vitrolife.com, +46 31 721 80 01 Mikael Engblom, CFO, mengblom@vitrolife.com, +46 31 721 80 14
Slide 11: Disclaimer
DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i